Precision drugs and gene therapy treatments to activate pro-survival pathways in selected neuronal populations

We investigate molecular mechanisms promoting functional maintenance of dopaminergic neurons, a neuronal population predominantly affected in Parkinson’s disease patients. We are aiming to find novel drugs and therapeutic strategies to support survival of dopaminergic neurons and protect them from cellular stress and pathological protein aggregation.
@ADom_Lab

GDNF reduces accumulation of α-synuclein aggregates in cultured dopamine neurons & in a mouse model of #Parkinsonstwitter.com/i/web/status/1…

Interesting - Biotech firm Prothena Corp @ProthenaCorp announces that their alpha synuclein immunotherapy treatment… twitter.com/i/web/status/1…

Horsager et al. present evidence for the existence of two subtypes of Parkinson's disease: 'brain-first', which sta… twitter.com/i/web/status/1…

Initial results from the Phase II PD-STAT clinical trial assessing the cholesterol-lowering Simvastatin in… twitter.com/i/web/status/1…

Recent publications

RSS Feed

No results.